Anthony Paul Possemato

Title: **Anthony Paul Possemato: Pioneer in Cancer Research and Innovations**

Introduction

Anthony Paul Possemato is an accomplished inventor based in Worcester, MA, who has made significant contributions to the field of cancer research. With a remarkable portfolio of 17 patents, his work especially focuses on the identification and development of novel approaches for targeting specific proteins involved in lung cancer.

Latest Patents

Among his latest patents, Possemato highlights two notable innovations. The first is focused on the translocation and mutant ROS kinase in human non-small cell lung carcinoma (NSCLC). This invention unveils a novel gene translocation, specifically (4p15, 6q22), leading to a fusion protein that combines elements of the Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with the Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase. The resulting SLC34A2-ROS fusion protein is anticipated to contribute to the growth and survival of certain NSCLC tumors.

The second patent revolves around compositions designed for detecting mutant Anaplastic Lymphoma Kinase (ALK) in lung cancer. This innovation identifies gene deletions and translocations involving chromosome 2, which lead to fusion proteins that include parts of the ALK kinase alongside secondary proteins such as Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, known for retaining ALK's tyrosine kinase activity, is vital in the proliferation and sustenance of NSCLC carrying this mutation.

Career Highlights

Anthony Possemato is currently employed at Cell Signaling Technology, Inc., where he plays a pivotal role in advancing cancer research through innovative discoveries. His expertise in genetic mutations pertinent to lung cancer not only enhances understanding but also fosters the development of targeted therapies.

Collaborations

Throughout his career, Possemato has collaborated with numerous talented colleagues, including Ailan Guo and Klarisa Rikova. These collaborations amplify the impact of his innovations, promoting a dynamic exchange of ideas and research methodologies pertinent to cancer treatment breakthroughs.

Conclusion

Anthony Paul Possemato stands as a significant figure in the realm of cancer research innovations. With a strong portfolio of patents and impactful collaborations, his work continues to contribute to understanding and addressing the complexities of lung cancer. His continued efforts at Cell Signaling Technology, Inc. promise to drive forward the development of novel therapeutic strategies in the fight against cancer.